Combined hormone and chemo before surgery for HER2+ breast cancer
Part of Cancer clinical trials.
This trial tests combining hormone therapy with chemotherapy and targeted therapy before surgery for a type of breast cancer that is both hormone-receptor-positive (HR+) and HER2-positive. The goal is to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have newly diagnosed, early-stage (stage IIA to IIIC) breast cancer that hasn't been treated yet.
- Your cancer must test positive for both hormone receptors (HR+) and HER2, based on standard guidelines.
- You must be scheduled to receive at least 4 cycles of a specific chemotherapy regimen called TCHP.
- Your tumor must be classified as Luminal A, Luminal B, or HER2-enriched by a special genetic test (MammaPrint/BluePrint).
- You cannot have had breast cancer in the past 5 years or any other cancer in the past 2 years, and your breast cancer must not be recurrent or stage IV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for a certain type of breast cancer (hormone receptor-positive, HER2-negative, with fast-growing cells). The goal is to see if this combination shrinks tumors more effectively before removal.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
Hear when a new Breast Cancer - Infiltrating Ductal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.